Q5160 — Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg
Q5160 is a HCPCS Level II code for injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg. It belongs to the Temporary Codes section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
Physician fee schedule statusE
Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).
Global period: XXX
Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.
The CMS record for Q5160
- Long descriptor
- Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg
- Short descriptor
- Inj, jobevne, 10 mg
- Added
- January 1, 2026
- BETOS
- O1D
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to Q5160
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q5160 is not quite right, the correct code is very often within a few positions of it.
- Q5152Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg
- Q5153Injection, aflibercept-yszy (opuviz), biosimilar, 1 mg
- Q5154Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg
- Q5155Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg
- Q5156Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg
- Q5157Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg
- Q5158Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg
- Q5159Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg
- Q5161Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg
- Q5162Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg
- Q5164Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg
- Q5165Injection, denosumab-mobz (oziltus), biosimilar, 1 mg
- Q5166Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg
- Q5167Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg
- Q5168Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg
- Q5169Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg
Questions about Q5160
What is HCPCS code Q5160?
Q5160 is a HCPCS Level II code for injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg. It sits in the Temporary Codes section.
Does Medicare cover Q5160?
The CMS HCPCS file marks Q5160 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
How is Q5160 paid under the physician fee schedule?
Q5160 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).